Cosmetic Efficacy Evaluation of Hydraporin AI Cream in Individuals With Atopic Dermatitis and Psoriasis
NCT07918560, Not applicable, Not yet recruiting, Brainfarma Industria Química e Farmacêutica S/A
Trial 10
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
| Field | Value | Source |
|---|---|---|
| Title | Cosmetic Efficacy Evaluation of Hydraporin AI Cream in Individuals With Atopic Dermatitis and Psoriasis | ClinicalTrials.gov |
| NCT number | NCT07918560 | ClinicalTrials.gov |
| Status | Not yet recruiting | ClinicalTrials.gov |
| Phases | Not applicable | ClinicalTrials.gov |
| Enrollment | 42 participants, estimated | ClinicalTrials.gov |
| Lead sponsor | Brainfarma Industria Química e Farmacêutica S/A | ClinicalTrials.gov |
| Conditions | Atopic Dermatitis, Psoriasis | ClinicalTrials.gov |
| Interventions | Investigational cream | ClinicalTrials.gov |
| First posted | 2026-11-05 | ClinicalTrials.gov |
| Last updated | 2026-11-05 | ClinicalTrials.gov |
Registered outcomes 8
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description | Source |
|---|---|---|---|---|
| Primary | Participant-perceived efficacy of the investigational cream after 30 and 45 days of use | Day 30 and Day 45 | Assessment of participants' perception of the efficacy of the investigational cream using a participant-reported questionnaire evaluating skin symptoms, with responses rated on a 4-point scale ranging from 0 (not relevant) to 3 (very much), after 30 and 45 days of continuous use. | ClinicalTrials.gov |
| Secondary | Eczema Area and Severity Index (EASI) or Psoriasis Area and Severity Index (PASI) score after 30 and 45 days of use | Day 30 and Day 45 | Assessment of clinical disease severity using the Eczema Area and Severity Index (EASI) in participants with atopic dermatitis and the Psoriasis Area and Severity Index (PASI) in participants with psoriasis. For both scales, lower scores indicate less severe disease and higher scores indicate greater disease severity. | ClinicalTrials.gov |
| Secondary | Skin hydration measured by Corneometer® after 30 and 45 days of use | Day 30 and Day 45 | Assessment of skin hydration in lesional and non-lesional skin using Corneometer® measurements. Higher values indicate greater skin hydration. | ClinicalTrials.gov |
| Secondary | Transepidermal water loss measured by Tewameter® | Day 30 and Day 45 | Assessment of skin barrier integrity in lesional and non-lesional skin using transepidermal water loss measurements obtained with Tewameter®. Lower values indicate better skin barrier function. | ClinicalTrials.gov |
| Secondary | Skin pH measured by pHmeter® after 30 and 45 days of useDay 45 | Day 30 and Day 45 | Assessment of skin surface pH in lesional and non-lesional skin using pHmeter® measurements. | ClinicalTrials.gov |
| Secondary | Dermatology Life Quality Index (DLQI) score after 30 and 45 days of use | Day 30 and Day 45 | Assessment of quality of life using the Dermatology Life Quality Index (DLQI). Total scores range from 0 to 30, with higher scores indicating greater impairment of quality of life. | ClinicalTrials.gov |
| Secondary | Clinical improvement of target lesions assessed by standardized photography after 30 and 45 days of use | Day 30 and Day 45 | Assessment of clinical changes in target lesions through standardized photographic documentation. | ClinicalTrials.gov |
| Secondary | Use of topical corticosteroid rescue medication during the study period | Baseline through Day 45 | Assessment of the need for topical corticosteroid rescue medication during treatment with the investigational cream. | ClinicalTrials.gov |
Outcomes 0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as | Source |
|---|
Results by group 0
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units | Source |
|---|
Participant flow 0
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted | Source |
|---|
Adverse events 0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events | Source |
|---|
Adverse event totals 0
The totals the trial posted for each group.
| Total | Group | Affected | At risk | Source |
|---|
Papers 0
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as | Source |
|---|
Grants 0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
| Project | Title | Principal investigators | Organization | Funder | Fiscal years | Source |
|---|
Trial comparisons 0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison | Source |
|---|
Tests 0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
| Test | Named as | Source |
|---|
Source 5
| Field | Value | Source |
|---|---|---|
| Release | trials-2026-11-12-0.4.0 | ClinicalTrials.gov |
| Release manifest SHA-256 | 0f4a8d8c48aee2a7573ae0fa94ecbeab70c1adbe449bbc95c424bc7d3e97b9d4 | ClinicalTrials.gov |
| Registry capture | 2026-11-12 | ClinicalTrials.gov |
| Results copy, AACT | 2026-03-23 | ClinicalTrials.gov |
| NIH clinical studies file | 2026-11-13 | ClinicalTrials.gov |
Release trials-2026-11-12-0.4.0
ClinicalTrials.gov's posted results, through CTTI's AACT: ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299 ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
ClinicalTrials.gov: none stated ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
NIH RePORTER's clinical studies and project files: Public domain (NIH RePORTER)